Roman Kizyma Recognized Among The 100 Most Influential CEOs in Oncology in 2025

Roman Kizyma Recognized Among The 100 Most Influential CEOs in Oncology in 2025

Roman Kizyma is a pediatric oncologist and the General Director of the Clinical Center for Children’s Medicine in Lviv, a major pediatric oncology and bone marrow transplant hub in Western Ukraine. Under his leadership, the center has become a critical regional referral point for children with cancer, especially during the ongoing conflict in Ukraine, providing care to displaced children from frontline regions.

Dr. Kizyma is a co-founder of SAFER Ukraine, a collaborative initiative with St. Jude Children’s Research Hospital, which coordinates the triage and evacuation of children with cancer to specialized care facilities across Europe. This program ensures continuity of life-saving treatment for children affected by wartime disruptions.

He has participated in international pediatric oncology training programs, including St. Jude Global, and is involved in research on improving sustainable pediatric cancer care in Ukraine. Dr. Kizyma’s work demonstrates a model of resilience and regional coordination in pediatric oncology, bridging emergency response and long-term healthcare development in conflict settings.

The 100 CEOs featured here reflect the diversity and complexity of modern oncology leadership. In 2025, some lead the world’s largest cancer institutions; others guide specialized societies or emerging innovators. What unites them is responsibility: for millions of patients, for the integrity of science, and for the future direction of cancer care globally.

This list is not a celebration of power, but a recognition of stewardship, accountability, and impact – and of the leaders whose choices continue to shape the fight against cancer. For the many deserving individuals not mentioned in this list, we will continue to acknowledge, honor and elevate your voices in our daily publications from across the world.

See the full list of The 100 Most Influential CEOs in Oncology in 2025, and stay tuned for other special category nominations.